US2004063692A1PendingUtilityA1

Bazedoxifene treatment regimens

43
Assignee: WYETH CORPPriority: Jun 13, 2002Filed: Jun 13, 2003Published: Apr 1, 2004
Est. expiryJun 13, 2022(expired)· nominal 20-yr term from priority
Inventors:Barry KommSimon Nicholas JenkinsJames H. ErmerMark A. CollinsGeraldine FerronPol BoudesWendy Ann Dulin
A61P 9/00A61P 5/24A61P 3/06A61P 5/00A61P 5/30A61P 25/28A61P 19/08A61K 31/55A61P 19/10A61K 31/404A61K 31/40
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to extended dosing regimens for the selective estrogen receptor modulator bazedoxefine (1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1 H-indol-5-ol).

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of treating or inhibiting bone loss in a mammal in need thereof, which comprises administering an effective amount of bazedoxifene according to an extended dosing regimen.  
     
     
         2 . The method according to  claim 1 , wherein the bazedoxifene is bazedoxifene acetate.  
     
     
         3 . The method according to  claim 2 , wherein the bazedoxifene is administered once weekly  
     
     
         4 . The method according to  claim 2 , wherein the bazedoxifene is administered every second day.  
     
     
         5 . A method of lowering cholesterol, triglycerides, Lp(a), or LDL levels; inhibiting or treating hypercholesteremia; or hyperlipidemia; in a mammal in need thereof, which comprises administering an effective amount of bazedoxifene according to an extended dosing regimen.  
     
     
         6 . The method according to  claim 5 , wherein the bazedoxifene is bazedoxifene acetate.  
     
     
         7 . The method according to  claim 6 , wherein the bazedoxifene is administered once weekly  
     
     
         8 . The method according to  claim 6 , wherein the bazedoxifene is administered every second day.  
     
     
         9 . A method of treating or inhibiting cardiovascular disease in a mammal in need thereof, which comprises administering an effective amount of bazedoxifene according to an extended dosing regimen.  
     
     
         10 . The method according to  claim 9 , wherein the bazedoxifene is bazedoxifene acetate.  
     
     
         11 . The method according to  claim 10 , wherein the bazedoxifene is administered once weekly  
     
     
         12 . The method according to  claim 10 , wherein the bazedoxifene is administered every second day.  
     
     
         13 . A method of treating or inhibiting dementias, neurodegenerative disorders, and Alzheimer's disease; providing neuroprotection or cognition enhancement in a mammal in need thereof, which comprises administering an effective amount of bazedoxifene according to an extended dosing regimen.  
     
     
         14 . The method according to  claim 13 , wherein the bazedoxifene is bazedoxifene acetate.  
     
     
         15 . The method according to  claim 14 , wherein the bazedoxifene is administered once weekly  
     
     
         16 . The method according to  claim 14 , wherein the bazedoxifene is administered every second day.  
     
     
         17 . A method of treating or inhibiting osteoporosis in a mammal in need thereof, which comprises administering an effective amount of bazedoxifene according to an extended dosing regimen.  
     
     
         18 . The method according to  claim 17 , wherein the bazedoxifene is bazedoxifene acetate.  
     
     
         19 . The method according to  claim 18 , wherein the bazedoxifene is administered once weekly  
     
     
         20 . The method according to  claim 18 , wherein the bazedoxifene is administered every second day.

Join the waitlist — get patent alerts

Track US2004063692A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.